Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B - Trial NCT05808374
Access comprehensive clinical trial information for NCT05808374 through Pure Global AI's free database. This Phase 1 trial is sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. and is currently Recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 85 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Fujian Shengdi Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 1
Apr 30, 2023
May 31, 2024
Primary Outcome
Number of Adverse Events In Part 1,Number of Adverse Events In Part 2
Summary
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and
 pharmacodynamics of HRS-5635 in healthy adults and chronic hepatitis B. To explore the
 reasonable dosage of HRS-5635.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05808374
Non-Device Trial